HC Wainwright Brokers Decrease Earnings Estimates for LBRX

LB Pharmaceuticals Inc (NASDAQ:LBRX) – Investment analysts at HC Wainwright decreased their FY2026 EPS estimates for LB Pharmaceuticals in a report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($5.98) per share for the year, down from their prior forecast of ($5.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($5.87) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($1.57) EPS, Q2 2027 earnings at ($1.33) EPS, Q3 2027 earnings at ($1.24) EPS, Q4 2027 earnings at ($1.30) EPS and FY2027 earnings at ($5.44) EPS.

Several other research analysts also recently commented on LBRX. Roth Capital downgraded shares of LB Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $37.00 to $35.00 in a research report on Monday, October 5th. Raymond James Financial upgraded LB Pharmaceuticals to a “buy” rating in a research note on Monday, October 12th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of LB Pharmaceuticals in a report on Wednesday, November 4th. Needham & Company LLC assumed coverage on LB Pharmaceuticals in a research note on Friday, October 2nd. They issued a “buy” rating and a $68.00 price target on the stock. Finally, Wall Street Zen cut LB Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $57.40.

LB Pharmaceuticals Trading Down 0.4%

NASDAQ LBRX opened at $44.94 on Wednesday. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -9.73 and a beta of 0.82. The firm’s 50 day simple moving average is $40.47 and its 200 day simple moving average is $33.17. LB Pharmaceuticals has a 1 year low of $14.32 and a 1 year high of $50.16.

LB Pharmaceuticals (NASDAQ:LBRX) last issued its earnings results on Thursday, November 5th. The company reported ($1.79) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.18).

Institutional Investors Weigh In On LB Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in LBRX. Spruce Street Capital LP raised its stake in shares of LB Pharmaceuticals by 36.9% during the first quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company’s stock valued at $33,645,000 after acquiring an additional 370,566 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of LB Pharmaceuticals during the first quarter worth $1,613,000. Bank of New York Mellon Corp acquired a new position in shares of LB Pharmaceuticals during the second quarter worth $1,784,000. Stempoint Capital LP bought a new stake in shares of LB Pharmaceuticals in the first quarter worth $1,233,000. Finally, Eversept Partners LP bought a new stake in shares of LB Pharmaceuticals in the first quarter worth $2,471,000.

About LB Pharmaceuticals

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company’s lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.